TME Pharma N.V. announced that it will issue regular bonds with an aggregated nominal value of ?0.5855 million which will issued at discount to nominal value of 84.5% for gross proceeds of ?0.5 million on August 25, 2025. The transaction included participation from european investors, Chairman of the Supervisory Board, Maurizio PetitBon for the amount of ?0.026827 and company's CEO, Diede van den Ouden for the amount ?0.0586 . The bonds will mature on May 28, 2026 and will be repaid at maturity in cash at 93.5% of nominal value.
The company has also issued 6,387,055 units of attached private warrants with an exercise price of ?0.11 at a 2.12% premium to the share price calculated from the last 10-day volume weighted average price (VWAP).
